Cyclacel Hosting Research & Development Day
Provided By Globe Newswire
Last update: Oct 24, 2022
-Program Update on its CDK2/9 Inhibitor, Oral Fadraciclib, and Oral PLK1 Inhibitor, CYC140, for the Treatment of Advanced Solid Tumors and Lymphoma-
CYCLACEL PHARMACEUTICALS - CYCC 6 PERP
NASDAQ:CYCCP (5/8/2025, 8:00:01 PM)
4.05
+0.31 (+8.29%)
2.75
-0.84 (-23.4%)
Find more stocks in the Stock Screener
